Trademark: 97933272
Word
ALNUQLA
Status
Pending
Status Code
661
Status Date
Thursday, May 2, 2024
Serial Number
97933272
Mark Type
4
Filing Date
Friday, May 12, 2023

Trademark Owner History

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.

Trademark Events
Aug 2, 2023
Teas Change Of Owner Address Received
May 16, 2023
New Application Entered
May 18, 2023
New Application Office Supplied Data Entered
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Correspondence Received
Feb 7, 2024
Assigned To Examiner
Feb 14, 2024
Non-Final Action Written
Feb 14, 2024
Non-Final Action E-Mailed
Feb 14, 2024
Notification Of Non-Final Action E-Mailed
May 2, 2024
Correspondence Received In Law Office
May 2, 2024
Teas/Email Correspondence Entered
May 2, 2024
Teas Response To Office Action Received

Trademark Alertz updated from USPTO on 2030-01-24